Outcomes in Patients Receiving Treatment for Pulmonary Arterial Hypertension Associated With Repaired Congenital Heart Disease

BACKGROUND: Pulmonary arterial hypertension (PAH) is a common complication among patients with congenital heart disease (CHD). Despite advances in PAH treatment, evidence for the benefits of PAH therapies in CHD-PAH is limited. OBJECTIVES: This analysis aimed to evaluate outcomes in patients with repaired PAH-CHD receiving an approved PAH drug. METHODS: This was a pooled analysis including CHD-PAH patients whose CHD was repaired 

• Krasuski, R. A.
• Tobore, T.
• Studer, S.
• Jansa, P.
• Sitbon, O.
• Hoeper, M. M.
• Channick, R.
• Gaine, S.
• Lang, I.
• Chin, K.
• Pulido, T.
• Mehta, S.
• Torbicki, A.
• Sastry, B.
• Tang, X.
• McLaughlin, V.
• Reardon, L. C.